ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions
ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions, a Prospective, Randomised, International Trial: ShockFast IVL Trial
- Coronary Arterial Disease
- Calcified Coronary Artery Disease
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Shunmei Medical
- Enrolment target
- 120
- Started
- 16 February 2026
- Main results due
- 1 November 2026
- Study sites
- 13
- Registry updated
- 29 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Patients aged ≥18 years undergoing PCI for stable or unstable angina or staged procedure after successful treatment of a myocardial infarction where heart enzymes are decreasing Angiographic criteria: 2. Native de novo coronary lesions 3. Vessel diameter between 2.5mm - 4.0mm 4. Lesion Length: ≤40mm 5. Severe Calcification: 1. Calcification visible on the upper and the lower sides of the vessel wall in at least two angiographic projections that differ ≥ 60° from each other 2. Presence of severe calcified protruding noduli 6. No flow disturbances at baseline (Thrombolysis in Myocardial Infarction \[TIMI\] 3 flow at baseline) 7. Target lesion with diameter stenosis ≥70% by visual, or ≥50% with evidence of clinical ischemia OCT Criteria: 8. Total calcium arc \> 180° or 9. Presence of a protruding calcified noduli Exclusion Criteria: 1. Ejection fraction less than 25% 2. Lesion located in Left Main (LM) coronary artery 3. Calcifications located mostly \> 0.5 mm from the vessel lumen. 4. Severe renal Impairment; Serum Creatinine \> 220 μmol or currently undergoing hemodialysis 5. Severe lesion tortuosity where OCT is judged impossible to cross. 6. Inability to tolerate dual antiplatelet therapy for 6 months or longer 7. Inability to obtain inform consent or deemed poorly compliant by the investigator 8. Presence of permanent pacemaker 9. Angiographic evidence of thrombus in the target vessel 10. Target lesion located at or involving within 5mm of the coronary ostium of the Left Anterior Descending artery (LAD), Left Circumflex artery (LCX) 11. Target lesion is a chronic total occlusion (CTO) 12. Presence of aneurysm within 10mm proximal or distal to the target lesion
What this study is about
In the sponsor’s own words, from the registry.
Coronary artery disease is caused by narrowing of the artery lumen. Treatment with Percutaneous Coronary Intervention (PCI) may be needed. This is a minimally invasive procedure used to treat narrowed or blocked coronary arteries. Sometimes a stent is placed to keep the artery open. If the lesions in the coronary artery are calcified, this may cause difficulties for successful stent placement. The calcified plaques can be fractured via intravascular lithotripsy (IVL) with devices like ShockWave IVL and ShockFast IVL. The aim of this study is to compare the this relatively new ShockFast IVl with the more widely used ShockWave IVL.
Study sites(13)
Infirmerie Protestante de Lyon
Lyon, France
Recruiting
Centre Cardiologique du Nord
Paris, France
Recruiting
Centre Hospitalier de Valenciennes
Valenciennes, France
Withdrawn
Segeberger Kliniken GMBH / Herz- und Gefäßzentrum
Bad Segeberg, Germany
Recruiting
MediClin Heart Center Lahr
Lahr, Germany
Not yet recruiting
Medical University of Silesia
Katowice, Poland
Not yet recruiting
University Hospital Krakow
Krakow, Poland
Not yet recruiting
Miedziowe Centrum Zdrowia
Lubin, Poland
Recruiting
Regional Specialist Hospital
Wroclaw, Poland
Recruiting
La Paz University Hospital
Madrid, Spain
Recruiting
La Princesa Univeristy Hospital
Madrid, Spain
Recruiting
Virgen Arrixaca University Clinical Hospital
Murcia, Spain
Recruiting
Virgen del Rocío University Hospital
Seville, Spain
Recruiting
Showing 13 of 13 sites. 9 of the 13 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07407738. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me